From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

About this update from Vortex Energy Corp.

[{"type":"text","content":"From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes DiabetesIssued on behalf of Avant Technologies Inc.\n\n\n\n VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) --\n \n\n USA News Group\n \n\n\n News Commentary\n \n –\n \n Stanford\n \n researchers achieved complete diabetes reversal in mice using a combined blood stem cell and islet transplant that eliminates the need for insulin or immunosuppressive drugs\n \n [1]\n \n . Meanwhile, stem cell therapies are restoring natural insulin production in human trials, with some patients achieving insulin independence for over a year\n \n [2]\n \n . As the healthcare industry pivots from managing symptoms to engineering biological solutions, five companies are positioning themselves at the forefront of this regenerative revolution:\n \n Avant Technologies, Inc.\n \n (OTCQB: AVAI),\n \n Vertex Pharmaceuticals Incorporated\n \n (NASDAQ: VRTX),\n \n Novo Nordisk\n \n (NYSE: NVO),\n \n CRISPR Therapeutics\n \n (NASDAQ: CRSP), and\n \n Sernova Biotherapeutics\n \n (TSX: SVA) (OTCPK: SEOVF).\n \n\n Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care\n \n [3]\n \n . Regenerative approaches are gaining momentum as regulatory frameworks expand to accommodate next-generation treatments, creating a narrow window for early investors to position themselves before these functional cures become standard of care\n \n [4]\n \n .\n \n\n\n Avant Technologies, Inc.\n \n (OTCQB: AVAI) has\n \n highlighted the critical role\n \n of cell encapsulation technology in enabling effective, long-term treatments for type 1 and insulin-dependent type 2 diabetes. Through\n \n Insulinova, Inc.\n \n , a joint venture with\n \n SGAustria Pte. Ltd.\n \n , the company is advancing a proprietary differentiation process achieving high-efficiency conversion of stem cells into insulin-producing and regulating cells, targeting type 1 and insulin-dependent type 2 diabetes patients globally. This innovative approach addresses a fundamental challenge: the immune system's rejection of implanted cells, which historically required lifelong immunosuppressive drugs carrying significant risks.\n \n\n \"Cell encapsulation is a game-changer in the field of regenerative me...

More updates from Vortex Energy Corp.